Neurodegenerative Diseases Market to 2018 – New Product Entries in both Niche and Broader Parkinson’s Disease Treatment will Boost Market Despite Patent Cliff...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11
2 Neurodegenerative Diseases Market to 2018: Introduction 13
3 Neurodegenerative Diseases Market to 2018: Global Market Overview 14
3.1 Revenue 14
3.2 Treatment Usage Pattern 16
3.3 Distribution by Market 17
3.4 Drivers and Restraints of the Neurodegenerative Diseases Market 18
3.4.1 Drivers 18
3.4.2 Restraints 18
4 Therapeutic Landscape 19
4.1 Market for Alzheimer’s Disease 19
4.1.1 Introduction 19
4.1.2 Revenue and Forecasts 21
4.1.3 Treatment Usage Pattern 23
4.1.4 Geographical Landscape 24
4.1.5 Drivers and Restraints for the Alzheimer’s Disease Market 46
4.2 Market for Parkinson’s Disease 47
4.2.1 Introduction 47
4.2.2 Revenue and Forecasts 49
4.2.3 Treatment Usage Pattern 50
4.2.4 Geographical Landscape 51
4.2.5 Drivers and Restraints for the Parkinson’s Disease Market 73
4.3 Market for Amyotrophic Lateral Sclerosis 74
4.3.1 Introduction 74
4.3.2 Revenue and Forecasts 76
4.3.3 Treatment Usage Pattern 77
4.3.4 Geographical Landscape 78
4.3.5 Drivers and Restraints for the Amyotrophic Lateral Sclerosis Market 100
4.4 Market for Huntington’s Disease 101
4.4.1 Introduction 101
4.4.2 Revenue and Forecasts 103
4.4.3 Treatment Usage Pattern 104
4.4.4 Geographical Landscape 105
4.4.5 Drivers and Restraints for the Huntington’s Disease Market 127
5 Neurodegenerative Diseases Market: Pipeline Analysis 128
5.1 Introduction 128
5.2 Summary of the Current Neurodegenerative Diseases R&D Pipeline 129
5.2.1 Alzheimer’s Disease 129
5.2.2 Amyotrophic Lateral Sclerosis 142
5.2.3 Parkinson’s Disease 147
5.2.4 Huntington’s Disease 155
6 Neurodegenerative Diseases Market: Deals and Strategic Consolidations 158
6.1 Merger and Acquisition Deals 158
6.1.1 Sanofi-Synthelabo Merges with Aventis 160
6.1.2 Bayer Acquires Schering 160
6.1.3 Takeda Pharma Completes Acquisition of Nycomed International for $13,681m 160
6.1.4 Teva Pharma Acquires Ivax 160
6.1.5 Abbott Labs Acquires Solvay Pharma 160
6.1.6 Teva Completes Acquisition of Cephalon for $6.8 billion 160
6.1.7 UCB Acquires 87.62% Stake in Schwarz Pharma 161
6.1.8 Biovail Acquires Valeant Pharma 161
6.1.9 Dainippon Sumitomo Pharma Completes Acquisition of Sepracor for $2.6 Billion 161
6.1.10 Merck Acquires Banyu Pharma 161
6.1.11 Amgen Completes Acquisition of Micromet for $1.2 Billion 161
6.1.12 Bayer Acquires Minority Stake in Bayer Schering Pharma 161
6.1.13 Daiichi Sankyo Completes Acquisition of Plexxikon 162
6.1.14 Lundbeck Acquires Ovation Pharma 162
6.1.15 Eli Lilly and Company Acquires Avid RadioPharma 162
6.1.16 Abbott Labs Completes Acquisition of Facet Biotech 162
6.1.17 Biogen Idec Acquires Fumapharm 162
6.1.18 Upsher-Smith Completes Acquisition of Remaining 84% Stake in Proximagen for up to $555m 163
6.1.19 Sun Pharma Acquires Controlling Stake in Taro Pharma 163
6.1.20 Pfizer Acquires Rinat Neuroscience 163
6.1.21 Cubist Pharma Completes Acquisition of Adolor for $415m 163
6.1.22 Biogen Idec Acquires Panima Pharma 164
6.1.23 Teva Pharma Acquires CoGenesys from New Enterprise, Orbimed and Red Abbey 164
6.1.24 Fujifilm Holdings Acquires 66% Stake in Toyama Chemical 164
6.1.25 MGI PHARMA Acquires Guilford Pharma 164
6.1.26 H. Lundbeck Acquires LifeHealth 164
6.1.27 Endo Pharma Completes Acquisition of Penwest Pharma 165
6.1.28 EPIX Pharma Acquires Predix Pharma 165
6.1.29 Biogen Idec Acquires Syntonix Pharmaceuticals 165
6.1.30 Biotie Therapies Acquires Synosia Therapeutics 165
6.2 Licensing Agreements 166
6.2.1 Cephalon Enters into a Licensing Agreement with Mesoblast for Regenerative Medicine 167
6.2.2 Idera Pharma Enters into a Licensing Agreement with Merck 167
6.2.3 Astellas Pharma Enters into Licensing Agreement with CoMentis for Beta-Secretase Inhibitors 167
6.2.4 Synosia Therapeutics Enters into Licensing Agreement with UCB for SYN-115 and SYN-118 167
6.2.5 GlaxoSmithKline Signs an Agreement with AFFiRiS 168
6.2.6 Biogen Enters into an Agreement with Acorda Therapeutics 168
6.2.7 BioMS Medical Enters into Licensing Agreement with Eli Lilly 168
6.2.8 AC Immune Enters into Licensing Agreement with Genentech for Anti-Tau Antibodies 168
6.2.9 Biovail Enters into Licensing Agreement with Acadia Pharmaceuticals 168
6.2.10 Biogen Idec Enters into Licensing Agreement with Knopp Neurosciences for KNS-760704 169
6.2.11 AstraZeneca Enters into Licensing Agreement with Targacept 169
6.2.12 AC Immune Enters into Licensing Agreement with Genentech 169
6.2.13 Proximagen Enters into Licensing Agreement with Upsher-Smith Labs 169
6.2.14 Merck Serono Enters into Licensing Agreement with Apitope Technology 170
6.2.15 Serono Enters into Licensing Agreement with Newron Pharma for Safinamide 170
6.2.16 Shire Exercises Option to License Adenosine A2A from Heptares Therapeutics 170
6.2.17 GlaxoSmithKline Enters into Licensing Agreement with Impax Pharma for IPX066 170
6.2.18 Santhera Pharmaceuticals Enters into Licensing Agreement with Ipsen for Fipamezole 171
6.2.19 Domain Therapeutics Enters into Licensing Agreement with Merck Serono 171
6.2.20 Addex Pharma Enters into Collaboration and Licensing Agreement with Merck & Co 171
6.2.21 Curis Enters into Licensing Agreement with Wyeth Pharma 171
6.2.22 Pfizer Enters into a License and Collaboration Agreement with Transtech Pharma 171
6.2.23 Antisense Therapeutics Enters into Licensing Agreement with Teva Pharma 172
6.2.24 Biogen Idec Enters into Licensing Agreement with Vernalis 172
6.3 Co-Development Deals 173
6.3.1 GlaxoSmithKline Signs an Agreement with Targacept 174
6.3.2 GlaxoSmithKline Enters into an Agreement with EPIX Pharma 174
6.3.3 Evotec Enters into Co-Development Agreement with Roche 174
6.3.4 Pfizer Enters into Co-Development Agreement with Medivation for Dimebon 174
6.3.5 Alectos Therapeutics Enters into Research Collaboration with Merck & Co 174
6.3.6 Targacept Expands its Collaboration Agreement with AstraZeneca 175
6.3.7 Boehringer Ingelheim Partners with Vitae Pharma 175
6.3.8 Elan Enters into Co-Development Agreement with Transition Therapeutics 175
6.3.9 Ceregene Enters into Agreement with Genzyme 175
7 Appendix 176
7.1 Market Definitions 176
7.2 Abbreviations 176
7.3 Sources 177
7.4 Research Methodology 179
7.4.1 Coverage 180
7.4.2 Secondary Research 180
7.4.3 Primary Research 180
7.5 Therapeutic Landscape 181
7.5.1 Epidemiology-based Forecasting 181
7.5.2 Market Size by Geography 182
7.6 Geographical Landscape 183
7.7 Pipeline Analysis 184
7.8 Competitive Landscape 184
7.8.1 Expert Panel Validation 184
7.9 Contact Us 184
7.10 Disclaimer 184